| 引用本文:梁菲1，燕腾飞1，王久利1，徐海军1，梁海2.扶正安中汤联合索拉非尼在中晚期肝癌患者的临床观察[J].世界中医药,2024,(03):. |
|
| 扶正安中汤联合索拉非尼在中晚期肝癌患者的临床观察 |
| Clinical Efficacy of Fuzheng Anzhong Decoction Combined with Sorafenib in Patients with Intermediate-to-advanced Liver Cancer |
| 投稿时间：2023-09-19 |
| DOI：10.3969/j.issn.1673-7202.2024.03.014 |
| 中文关键词: 原发性肝癌；扶正安中汤；索拉非尼 肝动脉化疗栓塞术；临床观察；肿瘤标志物；炎症介质；不良反应 |
| English Keywords:Primary liver cancer Fuzheng Anzhong Decoction Sorafenib Transcatheter arterial chemoembolization Clinical observation Tumor markers Inflammatory factor Adverse reactions |
| 基金项目:安徽省重点研究与开发计划项目（2022e07020066） |
|
| 摘要点击次数: 393 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨扶正安中汤联合索拉非尼（SOR）治疗肝动脉插管化疗栓塞术（TACE）后中晚期肝细胞癌（HCC）患者的临床效果。方法：选取2021年1至12月亳州市中医院肿瘤科收治的TACE后的中晚期HCC患者100例作为研究对象，用简单随机化分组方法分为对照组和观察组，每组50例。对照组采用SOR治疗，观察组采用SOR联合扶正安中汤治疗，持续治疗3个疗程后予以疗效评估，随访1年；比较2组治疗前后中医证候积分、肝功能、肾功能、肿瘤标志物及炎症介质水平指标；统计1年患者生存情况及用药安全性。结果：对照组和观察组疾病控制率分别为24.00%和56.00%（P<0.05）。治疗后，2组患者中医证候积分、血清指标谷草转氨酶（GOT）、谷丙转氨酶（GPT）、白蛋白（ALB）、总胆红素（TB）较治疗前下降，且对照组高于观察组（均P<0.05）；2组患者血清肌酐（Cr）、尿素氮（BUN）较治疗前升高，且对照组低于观察组，但差异无统计学意义（P>0.05）。1年随访期间对照组和观察组生存率分别为24.00%和42.00%，组间差异显著（χ2=8.72，P=0.0018）。2组血清恶性肿瘤特异性生长因子（TSGF)、血清甲胎蛋白（AFP）、血管内皮生长因子(VEGF)、肿瘤坏死因子-α(TNF-α)及白细胞介素-6（IL-6）水平较治疗前下降，且对照组高于观察组（P<0.05）。结论：扶正安中汤联合SOR是治疗TACE后中晚期HCC患者的有效方案。相对于单独使用SOR治疗，能有效调节血清肿瘤标志物及炎症介质水平，且不增加药物治疗风险。 |
| English Summary: |
| To explore the clinical efficacy of Fuzheng Anzhong Decoction combined with sorafenib(SOR) in the treatment of patients with intermediate-to-advanced liver cancer after transcatheter arterial chemoembolization(TACE).Methods:A total of 100 patients with intermediate-to-advanced liver cancer who underwent TACE at the Oncology Department of Bozhou Hospital of Traditional Chinese Medicine from January to December 2021 were selected.They were randomly divided into a control group and an observation group，with 50 cases in each group.The control group was treated with SOR alone，while the observation group was treated with Fuzheng Anzhong Decoction combined with SOR.The treatment efficacy was evaluated after three courses of treatment，and the patients were followed up for one year.The changes in traditional Chinese medicine(TCM) syndrome scores，liver function，renal function，tumor markers，and levels of inflammatory mediators before and after treatment were compared between the two groups.The one-year survival rate and drug safety of the patients were also analyzed.Results:The disease control rates in the control group and the observation group were 24.00% and 56.00%，respectively(P<0.05).After treatment，the TCM syndrome scores and serum indicators including glutamic oxaloacetic transaminase(GOT)，glutamic pyruvic transaminase(GPT)，albumin(ALB)，and total bilirubin(TB) decreased compared to those before treatment in both groups，with the control group being higher than the observation group(all P<0.05).The serum creatinine(Cr) and blood urea nitrogen(BUN) levels increased in both groups after treatment compared to those before treatment，with the control group being lower than the observation group，but the difference was not statistically significant(P>0.05).The one-year survival rates of the control group and the observation group during the follow-up period were 24.00% and 42.00%，respectively，with a significant difference between the groups(χ2=8.72，P=0.001 8).The levels of serum tumor-specific growth factor(TSGF)，alpha-fetoprotein(AFP)，vascular endothelial growth factor(VEGF)，tumor necrosis factor-alpha(TNF-α)，and interleukin-6(IL-6) decreased after treatment compared to those before treatment in both groups，with the control group being higher than the observation group(P<0.05).Conclusion:Fuzheng Anzhong Decoction combined with SOR is an effective regimen for treating patients with intermediate-to-advanced liver cancer after TACE.Compared with SOR alone，it can effectively regulate serum tumor markers and levels of inflammatory mediators without increasing the risk of drug treatment. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
